GenPro Selected to Lead Epigenetic Profiling on Multi-Company Multi-Institution Team Formed to Discover New Precision Medicine Hypotheses for Undiagnosed Diseases
We are passionately committed to applying our scientific expertise in a revolutionary computational genetic-analysis technology to transform standard next-generation DNA sequencing data into actionable information that enables researchers and clinicians to make precision medicine a reality for patients afflicted with life-threatening diseases.
Grounded in leading scientific discoveries and an experienced life-science business team, GenPro provides quantitative biomarker analysis of DNA methylation profiles for personalized health diagnostics, disease prediction, and therapeutic monitoring. Central to our approach is a proprietary analytical and profiling software platform that transforms routine DNA genome sequence data into deep insights into the dynamic epigenome of individual patients. GenPro's pioneering discoveries in epigenetic profiling give us the distinctive ability to identify new and important biomarkers for specific disease states. Our epigenetic analysis results provide clinicians and researchers with actionable information that supports faster, more confident decision making and enables better outcomes for patient health.
GenPro Analytics™, our proprietary, specialized software platform, employs genome-wide methylation profiling algorithms to discover novel epigenetic biomarkers that scientists and medical professionals can use to predict, diagnose, and monitor the likelihood and progression of disease in individuals with much more sensitivity, specificity, accuracy, and cost-effectiveness than any other approach available today.
Capitalizing on the exponential growth in next-generation sequencing (NGS) and the rising interest in and demand for epigenetic-profiling technologies and analysis of NGS data, GenPro Analytics™ drives transformational improvements across the entire NGS value chain while seamlessly integrating with current NGS pipelines and workflows. From reducing the cost, time, and complexity of preparing genomic DNA (gDNA) for sequencing to delivering highly sensitive and accurate quantitative whole-genome methylation profiles and novel epigenetic biomarkers, GenPro's cloud based analytical services enable biopharma, diagnostic, and NGS technology and service companies, and clinical-care research institutions, to achieve game-changing improvements in personalized disease prediction, diagnosis, and treatment.
The GenPro advantage starts with the simple addition of our gDNA prep kit to an existing whole-genome sequencing workflow. The restriction enzymes in this kit are matched to the GenPro Analytics™ methylation-profiling and biomarker-discovery software algorithms. Together, these technologies deliver results and provide answers that are superior to those obtained from the bisulfite oxidation approach typically used today. Our integrated technology:
As a result of these advances, researchers have access to highly sensitive, accurate, and comprehensive quantified methylation profiles for use in their own multivariate statistical analyses at a fraction of the cost of currently employed technologies. But more importantly, GenPro Analytics™ quantified methylation profiles enable previously unachievable downstream value generated by the discovery of novel epigenetic biomarkers that directly impact health improvements.
The most significant advantages of GenPro's technology are:
Dr. Serum is formerly vice president of R&D at Agilent and founder of Agilent's bio-science business, Jim brings 43 years' experience in analytical diagnostics as a scientist, entrepreneur, VC partner, and federal science and technology policy advisor engaged with NAS and NIST. He served on the board of directors of numerous emerging technology companies at various stages of commercial development.
Tracy brings over 20 years' experience in commercial operations leadership roles in life-science ventures within large companies including DuPont, Monsanto, WL Gore and Associates, and FMC Corporation.
Ian moved from Siemens Healthcare Diagnostics, where he was VP, head of the Strategic Innovation group, to the position of CSO of the Advanced Clinical Bio-Systems Institute at Cedars-Sinai Medical Center. His career spans over 30 years in life-science commercialization and technology development.
Genome Profiling, LLC (GenPro) was recently selected to participate and collaborate with four leading precision medicine technology providers and prominent experts from medical centers and universities across the country in the Undiagnosed Disease (UnDx) Consortium to produce new diagnostic and treatment hypotheses for an initial set of six patients struggling with undiagnosed diseases. GenPro will be providing the epigenetic profiling expertise within the multidisciplinary precision medicine approach that, combined with gene sequencing provided by Illumina, is tasked to elucidate new insights into causes and remedies for these difficult medical cases.Read More
Genome Profiling, LLC (GenPro), a molecular information company focused on discovering novel epigenetic biomarkers and translating them into new clinically valuable precision assays, and new insights into pathways, MOA’s, and potential therapeutic targets, announced that Adam Marsh, Ph. D., Chief Science Officer and Co-Founder, will present recent data illuminating the efficacy of epigenetic biomarker discovery and the game-changing potential they can deliver across many diseases and applications during the Eighth Annual Next Generation Dx Summit held in Washington DC on August 22-26 at 12:30 pm in the “Predictive Cancer Biomarkers” symposia.Read More
Adam Marsh, Ph. D, Chief Science Officer and Co-Founder of Genome Profiling, LLC, will present novel data demonstrating the potential power of epigenetic biomarkers to deliver new clinical value for Companion Diagnostics Applications during The Biomarker Conference, at the Fourpoints by Sheraton Conference Center in San Diego on February 18 – 19, 2016 at 10:30 am in the “Novel Technologies and Approaches” session.Read More